PhaseBio Pharmaceuticals, a Phase 2 biotech developing therapies for rare cardiopulmonary diseases, raised $46 million by offering 9.2 million shares (vs. 5.0 million originally) at $5, below the range of $12 to $14. PhaseBio Pharmaceuticals plans to list on the Nasdaq under the symbol PHAS. Citi, Cowen and Stifel acted as lead managers on the deal.
